Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
23.04.2021 Please participate in the TILs-Survey
The International Immuno-Oncology Biomarker Working Group has launched a global survey on the potential use of Tumor Infiltrating Lymphocytes (TILs) for future trial designs and use in daily practice.
20.04.2021 GBG Research at ESMO Breast Cancer Virtual Meeting 2021
We are delighted to inform you that results of several research projects from GBG and collaborative groups will be presented at the upcoming ESMO Breast Cancer Virtual Meeting 2021, which will take place from 5 to 8 May 2021.
13.04.2021 April 2021: First results of the randomized phase III PenelopeB trial
We are delighted to inform you that the first results of the randomized phase III PenelopeB trial have been published on a Rapid Communications basis in Journal of Clinical Oncology.
13.04.2021 March 2021: Predicting prognosis of breast cancer patients with brain metastases
An analysis including breast cancer patients with brain metastases from the BMBC registry has been published in Cancers
29.03.2021 ESMO BREAST CANCER 2021 - Virtual Meeting
Registration for the ESMO Breast Cancer Virtual Meeting, taking place 5-8 May 2021 is now open.
01.03.2021 Vorträge des Jahrestreffens verfügbar
Wir danken den Referenten, Teilnehmern und Organisatoren für das tolle virtuelle Jahrestreffen. Die Präsentationen finden Sie auf unserer Website zum Download und als Video zum Nachhören.
01.03.2021 17th St.Gallen International Breast Cancer Conference 2021
The 17th St.Gallen International Breast Cancer Conference is going fully virtual!
28.02.2021 February 2021: Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer
A translational research project investigating genomic patterns of mutational signatures in breast cancer patients from GeparSepto trial has been published in Annals of Oncology.
26.02.2021 January 2021: Final results of the MALE study
We are delighted to inform you that final results of the first randomized phase II MALE trial have been published in JAMA Oncology.
17.02.2021 OlympiA trial crossed superiority boundary for invasive disease-free survival
IDMC has concluded that OlympiA trial crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis. OlympiA Phase III trial of Lynparza in the adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer will be analysed and reported early.
17.02.2021 REGISTRIERUNG/ ANMELDUNG GBG Jahrestreffen 2021
GBG Jahrestreffen vom 24. bis 26. Februar 2021 wissenschaftliche Veranstaltung
04.02.2021 December 2020: Effect of germline BRCA1/2 mutations on haematological toxicities after neoadjuvant chemotherapy.
A retrospective analysis investigating the effect of germline BRCA1/2 mutations on severe haematological toxicities in TNBC patients treated with chemotherapy has been published in European Journal of Cancer.
28.01.2021 BIGPICTURE - Pathology Image Repository
A new consortium of the EU Innovative Medicines Initiative (IMI) will establish the biggest database of pathology images to accelerate the development of artificial intelligence in medicine.
21.01.2021 Covid-Impfung unter Chemotherapie
Entscheidungshilfen zur Durchführung einer COVID-19-Impfung bei Studienpatienten.
04.01.2021 AGO-Mamma State of the Art Meeting
Save the date: Virtuelles State of the Art Meeting am 27. Februar.
11.12.2020 November 2020: Effect of neoadjuvant chemotherapy on immune system in patients with TNBC
A translational research project evaluating effect of chemotherapy on different immune subsets in TNBC patients from GeparNuevo trial was published in Journal for ImmunoTherapy of Cancer
09.12.2020 GBG Research at SABCS Virtual Meeting 2020
Data on GBG study PenelopeB and several collaborative projects will be presented at the SABCS Virtual Meeting 2020.
13.11.2020 October 2020: Results from GeparOLA study
We are delighted to inform you that results from GeparOLA trial have been published in Annals of Oncology.
07.11.2020 GeparDouze-1000ste Patient randomisiert!
NSABP und GBG freuen sich bekannt zu geben, dass der 1000. Patient für die GeparDouze-Studie randomisiert wurde.
